Clinical trial
Can Resistance Enhance Selection of Treatment? (CREST)
NCT00262717 · Kirby Institute, Other · Completed
Key facts
| NCT number | NCT00262717 |
|---|---|
| Title | Can Resistance Enhance Selection of Treatment? (CREST) |
| Official title | A Randomised Comparator Study to Assess the Relative Efficacy of Genotypic Versus Virtual Phenotypic Resistance Tests in Treatment Experienced Patients With HIV Infection for Whom a Change in Therapy is Indicated |
| Lead sponsor | Kirby Institute, Other |
| Collaborators | Abbott Industry Boehringer Ingelheim GlaxoSmithKline Bristol-Myers Squibb Merck Sharp & Dohme LLC Roche Pharma AG Virco Diagnostic Technology Perkin Elmer Inc. |
| Status | Completed |
| Study type | Interventional |
| Conditions | HIV Infection |
| Intervention type | Diagnostic Test |
| Interventions | Blood test: genotype testing |
| Enrollment | 338 |
| Start date | Mar 1, 2001 |
| Primary completion | Jan 30, 2006 |
| Completion | Jul 31, 2006 |
| First posted | Dec 7, 2005 |
| Last update posted | Jun 26, 2025 |
| Countries | Australia |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: